BIOCON LTD. - 532523 - Announcement Under Regulation 30
Investor Meeting23-04-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release17-04-2024
BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended March 31, 2024.15-04-2024
BIOCON LTD. - 532523 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of Confirmation.12-04-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call for analysts/investors.10-04-2024
BIOCON LTD. - 532523 - Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Results And To Consider Recommendation Of Dividend, If Any, Amongst Other Routine Matters.
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 ,inter alia, to consider and approve Audited standalone and consolidated results and to consider recommendation of dividend, if any, amongst other routine matters.10-04-2024
BIOCON LTD. - 532523 - Intimation Under Regulation 30 (6) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) - Meeting Conducted With Institutional Investors/Research Analysts
Meeting conducted with Investors/ Research Analyst08-04-2024
Biocon leads India push into weight loss drugs as patents lapse
The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide injectible, which is losing patent protection in November.08-04-2024